NINDS supporting Emory/UF work on myotonic dystrophy

NINDS grant will support collaboration between Gary Bassell and Eric Wang on myotonic Read more

Antios moving ahead with potential drug vs hepatitis B

Antios Therapeutics is moving ahead clinical studies of an antiviral drug aimed at hepatitis Read more

Traynelis lead researcher on CureGRIN/Chan Zuckerberg award

The CureGRIN Foundation works closely with Emory pharmacologist Stephen Traynelis, who has been investigating rare genetic disorders affecting NMDA Read more

Jyothi Rengarajan

New animal model for elimination of latent TB

The significance of a recent Tulane/Yerkes study on eradicating latent tuberculosis in non-human primates may not be apparent at first glance. After all, it used the same antibiotic regimen (isoniazid + rifapentine) that is recommended by the CDC for human use.

But consider whether someone who was exposed to TB in childhood might still have it in their lungs somewhere. It’s difficult to know if treatments get rid of the bacteria completely.

“The antibiotic treatment we used for this study is a new, shorter regimen the CDC recommends for treating humans with latent tuberculosis, but we did not have direct evidence for whether it completely clears latent infection,” says Yerkes/Emory Vaccine Center researcher Jyothi Rengarajan, who was co-principal investigator along with Deepak Kaushal of Tulane. “Our experimental study in macaques showing almost complete sterilization of bacteria after treatment suggests this three-month regimen sterilizes humans as well.”

In an editorial in the same journal, CDC and Johns Hopkins experts call the results “dramatic” and say application of the drug regimen “could presage a major step forward in TB prevention and control.” Read more

Posted on by Quinn Eastman in Immunology Leave a comment